Original Article
Perceptions and Attitudes About Preexposure Prophylaxis Among Seronegative Partners and the Potential of Sexual Disinhibition
Abstract
Objectives: Preexposure prophylaxis (PrEP) is a promising strategy to prevent human immunodeficiency virus (HIV) infection, especially among high-risk individuals such as seronegative partners; however, many caveats such as the potential risk of sexual disinhibition and noncompliance need to be considered. We explored the sociodemographic and behavioral factors associated with the adoption of PrEP among HIV seronegative men who have sex with men and heterosexual partners.Methods: A prepiloted self-administered survey was conducted among seronegative partners in a Ryan White HIV/AIDS Clinic in South Carolina from 2010 to 2011. Bivariate and multivariable analyses were used to explore the data.
Results: The survey was completed by 89 seronegative partners. The median age was 42 years (interquartile range 32–50) and a majority was men (56%), black (70%), and heterosexual (74%). A majority (94%) was willing to use PrEP if available; however, 26% of subjects suggested that they would be more likely to have unprotected sex with an HIV-positive partner while using PrEP, and 27% suggested that it would be difficult to take a daily dose of PrEP and consistently use condoms. The multivariable results suggest that the belief that a condom is no longer needed while taking PrEP was more likely among those who did not use a condom during their last sexual intercourse (adjusted odds ratio 7.45; 95% confidence interval 1.57–35.45) and among those with a higher HIV knowledge score (adjusted odds ratio 0.43; 95% confidence interval 0.23–0.78).
Conclusions: Overall, these results suggest high acceptability of PrEP among seronegative partners to lower the risk of HIV transmission; however, there is a substantial risk of sexual disinhibition and noncompliance while using PrEP that may be reduced by ongoing education.
This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
References
1. Gostin LO, Kim SC. Ethical allocation of preexposure HIV prophylaxis. JAMA. 2011; 305: 191–192.
2. AVAC. PrEP resources. http://www.avac.org/ht/d/sp/i/354/pid/354. Accessed May 12, 2011.
3. Michael NL. Oral preexposure prophylaxis for HIV—another arrow in the quiver? N Engl J Med. 2010; 363: 2663–2665.
4. Myers GM, Mayer KH. Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings. AIDS Patient Care STDS. 2011; 25: 63–71.
5. Thigpen MC, Rose CE, Paxton LA. Antiretroviral preexposure prophylaxis for HIV prevention. N Engl J Med. 2013; 368: 82–83.
6. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363: 2587–2599.
7. Baeten J, Celum C. Antiretroviral pre-exposure prophylaxis for HIV-1 prevention among heterosexual African men and women: the Partners PrEP Study. http://www.hptn.org/web%20documents/WHRC/PartnersPrepStudy18Jul2011.pdf. Accessed January 3, 2012.
8. Van Damme L, Cornell A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012; 367: 411–422.
9. Centers for Disease Control and Prevention. PrEP: a new tool for HIV prevention. http://www.cdc.gov/hiv/prep/pdf/PREPfactsheet.pdf. Published August 2012. Accessed January 3, 2013.
10. Centers for Disease Control and Prevention. Update to interim guidance for preexposure prophylaxis (PrEP) for the prevention of HIV infection: PrEP for injecting drug users. MMWR Morb Mortal Wkly Rep. 2013; 62: 463–465.
11. Brooks RA, Kaplan RL, Lieber E, et al. Motivators, concerns, and barriers to adoption of preexposure prophylaxis for HIV prevention among gay and bisexual men in HIV-serodiscordant male relationships. AIDS Care. 2011; 23: 1136–1145.
12. Voetsch AC, Heffelfinger JD, Begley EB, et al. Knowledge and use of preexposure and postexposure prophylaxis among attendees of Minority Gay Pride events, 2005 through 2006. J Acquir Immune Defic Syndr. 2007; 46: 378–380.
13. Whiteside YO, Harris T, Scanlon C, et al. Self-perceived risk of HIV infection and attitudes about preexposure prophylaxis among sexually transmitted disease clinic attendees in South Carolina. AIDS Patient Care STDs. 2011; 25: 365–370.
14. Tripathi A, Ogbuanu C, Monger M, et al. Pre-exposure prophylaxis for HIV infection: healthcare providers’ knowledge, perception, and willingness to adopt future implementation in the southern US. South Med J. 2012; 105: 199–206.
15. Kim SC, Becker S, Dieffenbach C, et al. Planning for pre-exposure prophylaxis to prevent HIV transmission: challenges and opportunities. J Int AIDS Soc. 2010; 13: 24
16. Garcia-Lerma JG, Paxton L, Kilmarx PH, et al. Oral pre-exposure prophylaxis for HIV prevention. Trends Pharmacol Sci. 2010; 31: 74–81.
17. Paxton LA, Hope T, Jaffe HW. Pre-exposure prophylaxis for HIV infection: what if it works? Lancet. 2007; 370: 89–93.
18. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011; 365: 493–505.
19. SAS. Usage Note 32471. How do I test for equal variances, collinearity, or normality in logit, probit, poisson or other generalized linear models? Knowledge base/samples and SAS notes.http://support.sas.com/kb/32/471. Accessed October 17, 2011.
20. Mimiaga MJ, Case P, Johnson CV, et al. Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: limited knowledge and experience but potential for increased utilization after education. J Acquir Immune Defic Syndr. 2009; 50: 77–83.
21. Golub SA, Kowalczyk W, Weinberger CL, et al. Preexposure prophylaxis and predicted condom use among high-risk men who have sex with men. J Acquir Immune Defic Syndr. 2010; 54: 548–555.
22. Vanable PA, Carey MP, Brown JL, et al. What HIV-positive MSM want from sexual risk reduction interventions: findings from a qualitative study. AIDS Behav. 2012; 16: 554–563.
23. Ngure K, Mugo N, Celum C, et al. A qualitative study of barriers to consistent condom use among HIV-1 serodiscordant couples in Kenya. AIDS Care. 2012; 24: 509–516.
24. van der Straten A, Gomez CA, Saul J, et al. Sexual risk behaviors among heterosexual HIV serodiscordant couples in the era of post-exposure prevention and viral suppressive therapy. AIDS. 2000; 14: F47–F54.
25. Elam G, Macdonald N, Hickson FC, et al. Risky sexual behaviour in context: qualitative results from an investigation into risk factors for seroconversion among gay men who test for HIV. Sex Transm Infect. 2008; 84: 473–477.
26. Beckerman NL, Letteney S, Lorber K. Key Emotional issues for couples of mixed HIV status. Soc Work Health Care. 2000; 31: 25–41.
27. Desai K, Sansom SL, Ackers ML, et al. Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness. AIDS. 2008; 22: 1829–1839.
28. Holt M, Murphy DA, Callander D, et al. Willingness to use HIV pre-exposure prophylaxis and the likelihood of decreased condom use are both associated with unprotected anal intercourse and the perceived likelihood of becoming HIV positive among Australian gay and bisexual men. Sex Transm Infect. 2012; 88: 258–263.
29. Grohskopf L, Gvetadze R, Pathak S, et al. Preliminary analysis of biomedical data from the phase II clinical safety trial of tenofovir disoproxil fumarate (TDF) for HIV-1 pre-exposure prophylaxis (PrEP) among US men who have sex with men (MSM). http://pag.aids2010.org/Abstracts.aspx?AID=17777. Accessed August 27, 2013.
30. García-Lerma JG, Otten RA, Qari SH, et al. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med. 2008; 5: e28
31. Underhill K, Operario D, Mimiaga MJ, et al. Implementation science of pre-exposure prophylaxis: preparing for public use. Curr HIV/AIDS Rep. 2010; 7: 210–219.
32. Underhill K, Operario D, Skeer M, et al. Packaging PrEP to prevent HIV: an integrated framework to plan for pre-exposure prophylaxis implementation in clinical practice. J Acquir Immune Defic Syndr. 2010; 55: 8–13.
33. Centers for Disease Control and Prevention. CDC’s clinical studies of pre-exposure prophylaxis for HIV prevention. http://www.cdc.gov/hiv/prep/resources/qa/index.htm. Published 2010. Accessed January 4, 2010.
